The Relationship of CDK4 Expression with Histopathological Grade and Metastasis in Luminal Subtype Breast Cancer CDK4 in luminal breast tumors
Abstract
Background: The luminal (hormone receptor–positive/HER2–negative) subtype constitutes the majority of breast cancer cases. Despite a generally favorable prognosis, a significant proportion of patients experience metastasis. Cyclin-dependent kinase 4 (CDK4) is a key regulator of the cell cycle, and its dysregulation is a known driver of uncontrolled proliferation in luminal breast cancer. However, data on its association with adverse pathological features in the Indonesian population are limited. This study aimed to investigate the association between CDK4 expression, histopathological grade, and metastatic status in patients with luminal subtype breast cancer in Makassar, Indonesia.
Methods: This cross-sectional study included 74 patients with luminal subtype breast cancer. CDK4 expression in formalin-fixed, paraffin-embedded tumor tissues was assessed via immunohistochemistry and categorized as high or low. The association between CDK4 expression, histopathological grade, and metastatic status was evaluated using the χ2 test. Binary logistic regression was performed to calculate the odds ratio (OR) for metastasis.
Results: Of the 74 patients, 29 (39.2%) had metastatic disease. High CDK4 expression was significantly associated with high-grade tumors (P = 0.02) and with the presence of metastasis (P = 0.04). Patients with high CDK4 expression had 1.86 times higher odds of having metastasis compared with those with low CDK4 expression (OR, 1.86; 95% CI, 1.03–3.38).
Conclusion: Overexpression of CDK4 in luminal subtype breast cancer is significantly associated with higher histopathological grade and an increased likelihood of distant metastasis. This suggests CDK4 is a marker of more aggressive tumor biology and a potential prognostic marker in this patient population, warranting further investigation in longitudinal studies.
Full text article
References
Smolarz B, Zadrożna Nowak A, Romanowicz H. Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel). 2022; 14. doi:10.3390/cancers14102569. DOI: https://doi.org/10.3390/cancers14102569
Prihantono, Rusli R, Christeven R, Faruk M. Cancer Incidence and Mortality in a Tertiary Hospital in Indonesia: An 18-Year Data Review. Ethiop J Health Sci 2023; 33: 515–522. DOI: https://doi.org/10.4314/ejhs.v33i3.15
Anderson EJ, Mollon LE, Dean JL, Warholak TL, Aizer A, Platt EA et al. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer. Int J Breast Cancer 2020; 2020. doi:10.1155/2020/3759179. DOI: https://doi.org/10.1155/2020/3759179
Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Annals of Oncology 2020; 31. doi:10.1016/j.annonc.2019.11.006. DOI: https://doi.org/10.1016/j.annonc.2019.11.006
Lee MH, Cho JH, Kwon SY, Jung SJ, Lee JH. Clinicopathological characteristics of PIK3CA mutation and amplification in Korean patients with breast cancers. Int J Med Sci 2020; 17: 1131–1135. DOI: https://doi.org/10.7150/ijms.44319
Martínez-Saéz O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Research 2020; 22. doi:10.1186/s13058-020-01284-9. DOI: https://doi.org/10.1186/s13058-020-01284-9
Lammers SWM, Geurts SME, Hermans KEPE, Kooreman LFS, Swinkels ACP, Smorenburg CH et al. The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial. ESMO Open 2025; 10: 104154. DOI: https://doi.org/10.1016/j.esmoop.2025.104154
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology 2013; 24: 2206–2223. DOI: https://doi.org/10.1093/annonc/mdt303
Moura T, Caramelo O, Silva I, Silva S, Gonçalo M, Portilha MA et al. Early-Stage Luminal B-like Breast Cancer Exhibits a More Immunosuppressive Tumor Microenvironment than Luminal A-like Breast Cancer. Biomolecules 2025; 15: 78. DOI: https://doi.org/10.3390/biom15010078
Liang R, Weigand I, Lippert J, Kircher S, Altieri B, Steinhauer S et al. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. Front Endocrinol (Lausanne) 2020; 11. doi:10.3389/fendo.2020.00219. DOI: https://doi.org/10.3389/fendo.2020.00219
Peurala E, Koivunen P, Haapasaari K-M, Bloigu R, Jukkola-Vuorinen A. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res 2013; 15: R5. DOI: https://doi.org/10.1186/bcr3376
An H-X, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene Amplification and Overexpression of CDK4 in Sporadic Breast Carcinomas Is Associated with High Tumor Cell Proliferation. Am J Pathol 1999; 154: 113–118. DOI: https://doi.org/10.1016/S0002-9440(10)65257-1
Şahin AB, Cubukcu E, Ocak B, Deligonul A, Oyucu Orhan S, Tolunay S et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci Rep 2021; 11: 14662. DOI: https://doi.org/10.1038/s41598-021-94184-7
Pellarin I, Dall’Acqua A, Favero A, Segatto I, Rossi V, Crestan N et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther 2025; 10: 11. DOI: https://doi.org/10.1038/s41392-024-02080-z
Thu K, Soria-Bretones I, Mak T, Cescon D. Targeting the cell cycle in breast cancer: towards the next phase. Cell Cycle 2018; 17: 1871–1885. DOI: https://doi.org/10.1080/15384101.2018.1502567
Mayer EL. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer. Clin Adv Hematol Oncol 2015; 13: 215–7.
Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: From basic science to cancer therapy. Science (1979) 2022; 375. doi:10.1126/science.abc1495. DOI: https://doi.org/10.1126/science.abc1495
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel) 2021; 13. doi:10.3390/cancers13174287. DOI: https://doi.org/10.3390/cancers13174287
Polager S, Kalma Y, Berkovich E, Ginsberg D. E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene 2002; 21: 437–446. DOI: https://doi.org/10.1038/sj.onc.1205102
Du T, Yuan Y, Sun S, Gao Z, Li X. Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA. BMC Womens Health 2024; 24: 674. DOI: https://doi.org/10.1186/s12905-024-03486-1
Rampioni Vinciguerra GL, Sonego M, Segatto I, Dall’Acqua A, Vecchione A, Baldassarre G et al. CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. Front Oncol 2022; 12: 891580. DOI: https://doi.org/10.3389/fonc.2022.891580
Ziegler D V., Parashar K, Fajas L. Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer. Semin Cancer Biol 2024; 98: 51–63. DOI: https://doi.org/10.1016/j.semcancer.2023.12.002
Huang Z, Zhang Z, Zhou C, Liu L, Huang C. Epithelial–mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities. MedComm (Beijing) 2022; 3. doi:10.1002/mco2.144. DOI: https://doi.org/10.1002/mco2.144
Olea-Flores M, Zuñiga-Eulogio MD, Mendoza-Catalán MA, Rodríguez-Ruiz HA, Castañeda-Saucedo E, Ortuño-Pineda C et al. Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial–Mesenchymal Transition in Cancer. Int J Mol Sci 2019; 20: 2885. DOI: https://doi.org/10.3390/ijms20122885
M.Pevzner A, A.Gaptulbarova K, M.Tsyganov M, Κ.Ibragimova M, V.Vvedensky A, G.Zhusina Y et al. Investigation of somatic PIK3CA gene mutations in breast cancer patients. J BUON 2021; 26: 747–752.
Abidin Z. Peran Jalur Phosphatidyl-Inositol-3-kinase (PI3K) dalam Resistensi Kemoterapi pada Kanker. Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya 2018; 2. doi:10.30651/qm.v2i01.545. DOI: https://doi.org/10.30651/qm.v2i01.545
Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol 2018; 28: 911–925. DOI: https://doi.org/10.1016/j.tcb.2018.07.002
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 2024; 22: 331–357. DOI: https://doi.org/10.6004/jnccn.2024.0035
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2024; 35: 159–182. DOI: https://doi.org/10.1016/j.annonc.2023.11.016
Authors
Copyright (c) 2026 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.